ANI PHARMACEUTICALS, INC (ANIP) Return on equity 2016–2025
ANI PHARMACEUTICALS, INC (ANIP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.5%FY2025 · since FY2016: 2.3% → 14.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.5% | +19.1 pp |
| FY2024 | -4.6% | -8.9 pp |
| FY2023 | 4.3% | +19.6 pp |
| FY2022 | -15.3% | -2.5 pp |
| FY2021 | -12.8% | -1.2 pp |
| FY2020 | -11.5% | -14.4 pp |
| FY2019 | 2.9% | -5.0 pp |
| FY2018 | 7.9% | +8.5 pp |
| FY2017 | -0.6% | -2.9 pp |
| FY2016 | 2.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIP financial trends
ANIP RevenueANIP Net incomeANIP Net marginANIP Gross profitANIP Gross marginANIP Operating incomeANIP Operating marginANIP Operating cash flowANIP Free cash flowANIP Capital expendituresANIP Stock buybacksANIP Dividends paidANIP Total assetsANIP Total liabilitiesANIP Shareholders’ equityANIP overview →